Current Open Clinical Trials

COTC033: Repurposing Vaccine Immunity to Treat Cancers: Validation in Canine Patients

Purpose:

This clinical trial led by the National Cancer Institute (NCI) assesses the safety and effectiveness of intra-tumoral administered vaccines, when given to dogs with cancer. Studies in dogs with cancer will inform human trial designs to test new doses and effects of this agent.

Participating Sites:

Sponsor: The National Cancer Institute

Study Numbers: 20 dogs will be enrolled 

Eligibility Requirements:

  • Histologically confirmed solid tumor
  • Favorable performance status
  • Naïve or recurrent disease
  • Dogs must be more than 15kg
  • Dogs cannot receive concurrent chemotherapy or radiation for 2 weeks prior to study enrollment.
  • Dogs with Mast Cell tumor, hemangiosarcoma, thyroid carcinoma or lymphoma are not eligible.

COTC034: Clinical, Molecular, and immune characterization of naturally occurring osteosarcoma in dogs 

Purpose:

This trial is a single-armed trial where all dogs enrolled will receive treatment with amputation. The trial will evaluate the natural spectrum of outcomes for dogs treated with surgery alone for appendicular osteosarcoma.

Participating Sites:

Sponsor: The National Cancer Institute

Study Numbers: 20 dogs will be enrolled 

Eligibility Requirements:

  • Histologically confirmed osteosarcoma
  • Favorable performance status
  • Only newly diagnosed dogs
  • Dogs must be more than 25kg
  • No evidence of metastatic disease

COTC027: Preclinical Comparison of Two Hypomethylating Nucleosides in Tumor-Bearing Dogs

Purpose:

This clinical trial led by the National Cancer Institute (NCI) assesses the safety and effectiveness of TdCyd and Aza-TdC, novel anticancer agents, when given to dogs with cancer. Studies in dogs with cancer will complement currently open human trials designed to test new doses and effects of this agent.

Participating Sites:

Sponsor: The National Cancer Institute

Study Numbers: 30 dogs will be enrolled 

Eligibility Requirements:

  • Histologically confirmed lymphoma or solid tumor
  • Favorable performance status
  • Naïve or recurrent disease
  • Dogs must be more than 15kg
  • Dogs cannot receive concurrent chemotherapy, radiation or angiogenesis for 2 weeks prior to study enrollment.

COTC029: Pilot assessment of BG34-200 in spontaneous canine cancers

Purpose:

The purpose of this study is to evaluate dose escalation of BG34-200 in dogs with cancer. We will be evaluating 1) evaluate the safety of BG34-200, and 2) evaluate the ability of BG34-200 to stimulate a patient’s immune system to detect and destroy cancer cells.

Participating Sites:

Sponsor: Case Western Reserve University

Study Numbers: 6-10 dogs will be enrolled 

Eligibility Requirements:

  • Histologically confirmed solid tumor malignancy
  • Favorable performance status
  • Naïve or recurrent disease
  • Dogs must be more than 15kg
  • Dogs cannot receive concurrent chemotherapy, radiation or angiogenesis for 2 weeks prior to study enrollment.